RNA-Targeted Therapies (Amvuttra and Onpattro)
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy 2026D0072P alerts
Get alerted when Policy 2026D0072P changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit coverage and prior authorization for Amvuttra (vutrisiran) and Onpattro (patisiran) for UnitedHealthcare Commercial and Individual Exchange members. Coverage criteria address ATTR cardiomyopathy and hereditary ATTR polyneuropathy, including initial and continuation therapy.
Wainua (eplontersen) was added to the Review at Launch program, and some members may not be eligible for coverage at this time.
HCPCS codes C9311, J3490, and J3590 were added to the applicable codes section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.